| News

T3 Pharmaceuticals wins W.A. de Vigier Award

28.05.2019

T3 Pharmaceuticals is among the winners of this year’s W.A. de Vigier Award. The spin-off from the University of Basel is developing a targeted cancer therapy using bacteria.

T3 Pharma (img: Universität Basel, Basile Bornand)

T3 Pharmaceuticals is among the ten winners of this year’s W.A. de Vigier Award. The Basel startup impressed the jury with its targeted cancer therapy. T3 Pharmaceuticals employ living bacteria that have the capacity to specifically find and grow in solid tumors, where the bacteria serve as efficient factories for therapeutically active proteins. The startup was founded in 2015 out of a research project at the Biozentrum of the University of Basel. T3 Pharmaceuticals is a portfolio company of BaseLaunch.

With annual prize money of 500,000 Swiss francs, the W.A. de Vigier promotional award is the oldest and most financially significant award for startups in Switzerland. To mark its 30th anniversary, the W.A. de Vigier Foundation selected twice as many startups to win the award this year. What’s more, 60 startups were able to pitch to the jury rather than the usual 16. This year’s prize money also increased to 750,000 francs overall, with some of the funds being contributed by former award winners.

“I am particularly pleased that former winners contributed to this year’s prize money. I hope that in the future our alumni will increasingly partner up with each other to help established companies remain innovative and pave the way for young startups to enter the market,” said Regula Buob, Managing Director of the W.A. de Vigier Foundation. This is all in the spirit of the founding father Bill de Vigier.

Share this article

Sign up to receive our newsletter in your inbox.

You might also be interested in

Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Yokogawa establishes innovation center in Allschwil

The Japanese conglomerate Yokogawa has established a Swiss subsidiary based at the Switzerland Innovation Park Basel Area. Here, the focus will be on driving forward innovation in the field of biotechnology.

Read More
Basel Area Business & Innovation, Innovation, Invest

Basel gains new biotech in Bright Peak

Versant Ventures has made a US$35 million Series A funding commitment to Bright Peak Therapeutics and has now announced the debut of this biotech. It will operate in Basel and San Diego.

Read More
Basel Area Business & Innovation, Innovation, Switzerland Innovation Park

Robots from Basel set to revolutionize surgery

The Werner Siemens Foundation is to invest an additional 12 million Swiss francs in the Miracle project. Researchers at the University of Basel are developing visionary technology for the use of robots in surgery within the framework of this project.

Read More
Basel Area Business & Innovation, Innovation

T3 Pharma raises over 25 million Swiss francs

T3 Pharmaceuticals AG has closed its third financing round, raising over 25 million Swiss francs. The Basel-based startup has developed a bacterial cancer therapy that it now intends to progress to clinical trials.

Read More
Basel Area Business & Innovation, Innovation

Versameb raises 6 million Swiss francs

The Basel-based biopharmaceutical company Versameb has successfully closed a seed financing round. Versameb develops therapies on the basis of mRNA sequences and is now seeking to drive forward the clinical development of its platform devised for this.

Read More
Basel Area Business & Innovation, Innovation

Genedata accelerating drug development

Genedata, a Basel IT company specializing in the life sciences sector, has agreed a collaboration with Thermo Fisher. The integration of their two platforms will help accelerate the development of drugs.

Read More
Basel Area Business & Innovation, Innovation, Invest

Basel is “probably the most productive life sciences location in the world”

Two thirds of the value added attributable to the pharmaceutical industry as a whole in Switzerland is generated in the Basel Area, as revealed by an Interpharma report. However, the region also shines in an international comparison. Interpharma CEO René Buholzer regards it as “probably the most productive life sciences location in the world”.

Read More
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Basel Area cantons publish joint economic report

The cantons of Basel-Landschaft, Basel-Stadt and Jura have just published their first joint Economic Report. The fundamental environment is described as “good” in the report.

Read More
Basel Area Business & Innovation, Innovation

Resistell receives high-level EU grant

Resistell AG, based in Muttenz in the canton of Basel-Landschaft, has received a grant of up to 2.5 million euros and additional equity capital financing from a European fund with the aim of accelerating innovation. The company is developing the world’s fastest test against antibiotic resistance.

Read More
Novartis Campus
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Switzerland Innovation Park Basel Area Site Novartis Campus

We are happy to present our latest addition to the Switzerland Innovation Park Basel Area: Our site on the Novartis Campus dedicated to digital health provides a focal point to a unique community of digital healthcare experts.

Read More
1 2 3 19

Do you have a question? We'd like to hear from you.